



Bridging the Gap



ABC7 Advanced Breast Cancer Seventh International Consensus Conference

9-11 November 2023 Lisbon, Portugal

Chair:

F. Cardoso, PT

Honorary Chairs:

E.P. Winer, US - L. Norton, US - A. Costa, IT/CH

Co-Chair:

E. Schumacher-Wulf, DE

Scientific Committee Members:

S.X. Franco Millan, CO - K. Gelmon, CA

J. Gligorov, FR - V. Mueller, DE

B.V. Offersen, DK - S.M. Swain, US

The ABC7 guidelines will be developed by the Global Alliance



The ABC7 guidelines are endorsed by



The ABC7 conference is

held with support from



held under the auspices of



endorsed by



and held with official representatives of



ABC7 will be followed by the meeting of the **ABC GlobAlliance** on 11-12 November 2023.

ABC7 is being organised as hybrid meeting.

FINAL PROGRAMME

**1 IN 4 PEOPLE
WITH ADVANCED
BREAST CANCER
WILL BE ALIVE
5 YEARS AFTER
THEIR DIAGNOSIS¹**



*I used my
salary for
chemo and
had no
money for food*



*We had to
fight for the
right treatment*

I . . .
Do solemnly promise,
To combat the gaps in care.
So nobody feels like a burden,
Is shunned by their village,
Shamed by neighbours,
This is why I make this vow,
To close the gaps in breast cancer care.
So no one,
No one ever in the world,
Suffers poor care,
Or dies before they might,
Of Advanced Breast Cancer.

**The ABC Global Charter
has outlined 10 achievable
goals for the next 10 years
to drive change in advanced
breast cancer (ABC) care**



*Go home and
pray, there is
nothing we
can do for
you now.*


Be the change

www.abcglobalalliance.org


1. Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J, et al. Global analysis of advanced/metastatic breast cancer: decade report (2005-2015). *The Breast*. 2018 Jun;39:131-8.

Team

Partner journal



Dedicated Media Partner



Paulina Gono (1) pgono@abcglobalalliance.org	ABC Award nominations
	Communication and Social media, Travel Grants
Helder Carvalho (2) helder.carvalho@abreu.pt	Travel Grants
	Accommodation and Optional tours
Roberta Ventura (1) rventura@abcglobalalliance.org	Organisation, Programme, Exhibition, Satellite symposia and Sponsorship
Dolores Knupfer (1) abc7@abcglobalalliance.org	Abstracts, Accreditation
International media: Emma Mason and Kerry Noble info@ricemasonnoble.eu National media: Filipa Morais fm@publicrelations.pt	Press officers
info@abcglobalalliance.org	ABC Global Alliance inquiries

1. ABC Global Alliance c/o Fundação Champalimaud, Avenida de Brasília s/n 1400-038 Lisboa, Portugal	ph +351 936 773 761 ph +351 938 027 790
2. Viagens Abreu SA Av. 25 de Abril, 2 2799-556 Linda-a-Velha, Portugal	ph +351 214 156 120 fx +351 214 156 383

Foreword

Dear Colleagues,

It is with great pleasure that I invite you to join us at the Advanced Breast Cancer Seventh International Consensus Conference (ABC 7) that will take place in Lisbon, Portugal, on 9-11 November 2023.

The ABC Consensus Conference has established itself as the major international conference for advanced breast cancer. Its uniqueness resides in the central role of ABC patients and in its truly global reach. We strongly believe that health professionals working closely together with patients and advocates and with the strong support of the media can raise awareness and effectively lobby in favor of this previously underserved and often forgotten group of patients.

The conference's primary goal is the development of international consensus guidelines for the management of advanced breast cancer. These guidelines are based on the most up-to date evidence and can be used to guide treatment decision-making in a wide variety of different health care settings globally, with the necessary adaptations due to different access to care. Throughout the years, these guidelines have been endorsed by several international organizations, and many organizations around the world have been adapting them to their country specific environment, particularly in terms of promoting accessibility both to health care services and new therapeutic agents.

ABC also aims to be a forum to analyze and discuss the latest scientific updates in the field, to identify research priorities and important areas of unmet needs, as well as influence policy makers, regulatory and funding bodies and ultimately improve standards of care, survival and quality of life for all patients living with ABC worldwide.

The ABC consensus conference started from the desire to address and change the sense of abandonment and invisibility experienced by many patients with ABC patients and the urgent need to change their outcomes. In 2011 the European School of Oncology pioneered this initiative and today the conference has evolved and, is organized by the ABC Global Alliance.

The ABC Global Alliance is an independent non-profit multi-stakeholder organization dedicated exclusively to improve and extend the lives of women and men living with ABC worldwide, and currently has more than 200 members in over 90 countries worldwide.

Due to the COVID-19 pandemic, our last meeting (ABC 6) was held virtually and brought together around 1.000 participants from 67 countries around the world, including health professionals, patients, advocates, and journalists. Fortunately, this year, we will be able to meet again face-to-face and enjoy the powerful and passionate interactions among attendees. All topics will be presented from the perspective of a multidisciplinary approach, from basic research through to clinical implementation. The conference will again close with a consensus session aimed at updating the ABC guidelines.

It is my pleasure to invite you to join us in Lisbon for the 7th edition of the Advanced Breast Cancer International Consensus Conference (ABC7), and to work with us to improve the lives of all ABC patients.

Fatima Cardoso, MD
Chair of ABC 7 and President of the ABC Global Alliance

Acknowledgements

The ABC Global Alliance wishes to express its appreciation and gratitude to the ABC7 Chairs and Scientific Committee members for their support and vision in organising this conference, all faculty members and panellists, and members of the Patient Advocacy Committee for their commitment and contribution to the programme. Our gratitude is furthermore extended to The Breast and Cancer World for their cooperation, all organisations and companies for participating and supporting the initiative.

General information

Venue

ABC7 will take place as an onsite event Lisbon, 9-11 November 2023, at the CCL - Centro de Congressos de Lisboa, Praça das Industrias, Lisbon, Portugal (website: <https://ccl.lisbonvenues.pt/en/>) as well as online, through a dedicated virtual platform.

Official language

The official language of the event is English. No translation will be provided.

Insurance


The organisers bear no responsibility for untoward events in relation to the participation at the Conference. Participants are advised to take out their own personal and travel insurance coverage.

Abstract book

The abstract book will be published as a supplement of **The Breast** and contain abstracts from the invited lecturers and those abstracts that have been accepted for oral or poster presentation, or for publication only.


CME accreditation and certificates

Participants will be entitled to receive a certificate of attendance at the close of the Conference by completing the online evaluation questionnaire.

The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). 

The event is designated for a maximum of 15.5 European CME credits (ECMEC®s).

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™.

The Accreditation Council in Europe (ACOE) has awarded 15 credits to the conference. 

Filming, recording or photographing Conference sessions

All sessions except the Consensus session:

- Filming, recording and non-flash photography of speakers are permitted.
- Filming, recording and photography of slides are not permitted without the presenter's permission.

Consensus session:

- Filming, recording and photography are prohibited since the contents of the statements will be revised when published in the consensus paper.

Other areas of the Conference:

- Filming, recording and photography are permitted if prior permission has been given by the press officers.
- Filming, recording and photography of posters are not permitted without the author's permission.

Social media

Tweet, network and follow updates using **#ABClisbon** on X, LinkedIn and Facebook.



Third party media policy

The policy applies to all activities related to the news media during or in connection with ABC7. The media policy document is posted at www.abc-lisbon.org.

The aim of the policy is to ensure that information distributed to the journalists is accurate and is issued at the correct times, complying with any embargoes that may be in place.

The policy applies to media events that are organised at the ABC7 venue and off-site, and all third parties are requested to adhere.

Internet access

Free internet Wi-Fi access is available for conference delegates on Level 1. The network name is ABC7, no password is required.

No smoking policy

ABC7 is a tobacco-free event. All participants are kindly asked to respect the no-smoking policy.

Official carrier

The ABC Global Alliance is grateful to TAP Portugal, a Star Alliance member, who supported the Conference as the Official Carrier and offered discounted fares to the participants.



Conference speakers and panellists

Conference speakers and panellists are invited to refer to the speakers' room located on Level 1. Presentation files should be delivered to the appointed technician in the speakers' room 60 minutes or more before the start of the session.

Press office

Accredited journalists wearing a "Press" badge are invited to refer to the press office located on Level 1.

Coffee breaks, lunches and welcome cocktail (in-person participation)

Coffee breaks, lunches and welcome cocktail are available to all participants, media representatives and exhibitors during the published times. Buffets are organised on Level 1 in the poster and in the catering areas.

Furthermore, please note that the poster session is scheduled on Friday, 10 November during lunch time.

During the poster session, the appointed faculty members will visit and discuss the posters with the presenters and participants.

Registration desk, opening hours

Wednesday, 8 November 15:00 - 19:00
Thursday, 9 November 7:30 - 18:00
Friday, 10 November 7:30 - 18:00
Saturday, 11 November 7:30 - 13:00

Exhibition, opening hours

Thursday, 9 November 9:00 - 19:30
Friday, 10 November 8:30 - 19:30
Saturday, 11 November 8:30 - 13:00

Registration

In-person participation includes:

- Participation in scientific and educational live sessions
- Onsite networking
- Entry to the Poster Area
- Access to the Virtual Platform to watch the missed sessions on-demand and Abstract Book

- Coffee breaks, lunches, welcome cocktail as indicated in the programme

IN-PERSON PARTICIPATION	Full (from 17 October 2023)
Physicians, Industry and policy makers	EUR 700
ABC Global Alliance members	EUR 700
Caregivers** and researchers**	EUR 700
Emerging economies*, patient advocates**, students** and residents** in training	EUR 400

Online participation includes:

- Access to the virtual platform, with live streaming of all sessions and possibility to watch the sessions on-demand
- Interaction through the chat on the congress Virtual Platform
- Access to e-Posters
- Access to the Virtual Platform to watch the missed sessions on-demand and Abstract Book

ONLINE PARTICIPATION	Full (from 17 October 2023)
Physicians, Industry and policy makers	EUR 600
ABC Global Alliance members	EUR 600
Caregivers** and researchers**	EUR 600
Emerging economies*, patient advocates**, students** and residents** in training	EUR 400

Important

Representatives of exhibiting companies do not have access to the scientific and educational live sessions neither to the live streaming and on-demand sessions on the virtual platform but to all other services.

Online registration will be available at: www.abc-lisbon.org

Badge (In-person participation)

The badge is the only official evidence of registration and should be always worn during the event. Loss of badge results in loss of registration.

Media registration

The Conference welcomes representatives of print and electronic media. Registration is free of charge to journalists who are in possession of a valid, recognised press card. Freelance journalists must present a commissioning letter on headed paper from a recognised news organisation or publication. Representatives of advertising, marketing and public relations companies are not eligible for free media registration. A copy of the Press Card or of the commissioning letter should be submitted when making the registration online.

Public transportation passes

A limited number of free public transportation passes (with 8 tickets for metro and bus) are available for ABC7 participants and is distributed from the registrations desks on a first-come/first served basis.

GRASP Poster Walkthroughs


ABC7 is pleased to collaborate with GRASP - [Guiding Researchers and Advocates to Scientific Partnerships](#) - to offer their engaging and informative Poster Walkthroughs for the very first time at our conference!

GRASP is a patient-led program that recognizes each participant as an expert in their own right: oncologists are experts in treating patients with cancer, researchers are experts in studying cancer, and patients are experts in living with cancer. GRASP Poster Walkthroughs create the opportunity for learning exchanges between scientists and advocates. Patient involvement is instrumental in driving better research and making faster progress to end cancer. We hope that you will participate in this unique opportunity and help break down silos in research. **GRASP Poster Walkthroughs** will take place in Hall 4 on Friday, 10 November during the lunch break from 13:00-14:00.



If you are interested in participating, please join the [GRASP Network](#) and send us an email to grasp@graspcancer.org to inform of your interest in attending the Poster Walkthrough at ABC7.

ABC7 Scientific Committee



Chair
Fatima Cardoso
Breast Unit
Champalimaud Clinical
Center
Lisbon, PT




Scientific Committee Members
Sandra Ximena Franco Millan
Cancer Treatment and
Reserach Center
Bogota, CO



Honorary Chairs
Eric P. Winer
Yale Cancer Center
New Haven, US



Karen Gelmon
BC Cancer Agency,
Department of Medical
Oncology
Vancouver, CA



Larry Norton
Breast Cancer Programs,
Memorial Sloan-Kettering
Cancer Centre
New York, US



Joseph Gligorov
Department of Medical
Oncology, Cancer Est APHP
Tenon, University Paris VI
Paris, FR



Alberto Costa
CEO, European School of
Oncology
Milan, IT
and Bellinzona, CH




Volkmar Mueller
University Medical Center
Hamburg-Eppendorf
Hamburg, DE



Co-chair
Eva Schumacher-Wulf
Mamma Mia
Kronberg, DE



Birgitte V. Offersen
Department of Oncology,
Aarhus University Hospital
Aarhus, DK



Sandra M. Swain
Georgetown University
Medical Center and MedStar
Health
Washington DC, US

Faculty members

Matti S. Aapro

IMO Clinique de Genolier, Institut
Multidisciplinaire d'Oncologie, Genolier, CH

Isabelle Aloi-Timeus

Salvati Foundation AC, Mexico City, MX

Jyoti Bajpai

Tata Memorial Centre, HBNI, Mumbai, IN

Sarah-Jane Barker

Healthcare communications lead and ABC
caregiver, London, UK

Carlos H. Barrios

Department of Medicine, PUCRS School of
Medicine, Porto Alegre, BR

Elizabeth Bergsten-Nordström

Europa Donna -The European Breast Cancer
Coalition, SE

Laura Biganzoli

Department of Medical Oncology, Sandro
Pitigliani Oncology Centre, Prato, IT

Maria João Cardoso

Breast Unit, Champalimaud Cancer Center and
MamaHelp, Lisbon, PT

Lisa A. Carey

UNC Lineberger Comprehensive Cancer Center,
Chapel Hill, US

Mariana Chavez Mac Gregor

Health Services Research Breast Medical
Oncology The University of Texas
MD Anderson Cancer Center, Houston, US

Runcie C.W. Chidebe

Project PINKBLUE, Abuja, NG

Charlotte Coles

University of Cambridge, UK

Javier Cortés

International Breast Cancer Center (IBCC),
Madrid and Barcelona, ES

Lioe-Fee de Geus

University of Leiden, Leiden, NL

Rebecca A. Dent

National Cancer Center Singapore, Singapore, SG

André Dourado

Mama Help - Breast Cancer Support Center,
Porto, PT

Amanda Drury

Dublin City University, Dublin, IE

Vicky Durston

Breast Cancer Network Australia, Camberwell,
AU

Nagi S. El Saghir

NK Basile Cancer Institute American University
of Beirut Medical Center, Beirut, LB

Alexandru Eniu

Hopital Riviera-Chablais, Vaud-Valais
Rennaz, CH

Lesley Fallowfield

Brighton & Sussex Medical School, University of
Sussex, Brighton, UK

Prudence A. Francis

Division of Cancer Medicine, Peter MacCallum
Cancer Centre, Melbourne, AU

Jenny Gilchrist

The McGrath Foundation, St. Leonards, AU

William J. Gradishar

Northwestern Medicine, Illinois, US

Bishal Gyawali

Queen's University, Division of Cancer Care and
Epidemiology, Kingston, CA

Renate Haidinger

Brustkrebs Deutschland e.V., Munich, DE

Nadia Harbeck

Breast Centre, University of Munich, Munich, DE

Xichun Hu

Fudan University Shanghai Cancer Center,
Shanghai, CN

André Ilbawi

World Health Organization, Geneva, CH

Dimitris Kalogeropoulos

Global Health & Digital Innovation Foundation,
London, UK

Ranjit Kaur

Breast Cancer Welfare Association, Pataling Jaya,
MY

Belinda Kiely

NHMRC Clinical Trials Centre, Sydney Medical
School, Sydney, AU

Sung-Bae Kim

Asan Medical Centre, Department of Oncology,
Seoul, KR

Stella Kyriakides

European Commissioner for Health and Food
Safety, Brussels, BE

Marion Kuper-Hommel

Waikato Hospital, Midland Regional Cancer
Centre, Hamilton, NZ

Matteo Lambertini

IRCCS Ospedale Policlinico San Martino,
University of Genoa, Genoa, IT

Frédéric E. Lecouvet

Dept of Radiology, Centre du Cancer and Institut
de Recherche Expérimentale et Clinique (IREC),
Cliniques Universitaires Saint Luc, Université
Catholique de Louvain, Brussels, BE

Nanre Mampak

National Hospital Abuja, NG and University of
Rwanda, Kigali, RW

Ginny Mason

Inflammatory Breast Cancer Research
Foundation, West Lafayette, US

Leonor Matos

Champalimaud Clinical Center, Lisbon, PT

Claire Myerson

Breast Cancer Now, London, UK

Shirley A. Mertz

MBC US Alliance and Metastatic Breast Cancer
Network US, Inverness, US

Gertrude Nakigudde

Uganda Women's Cancer Support Organisation,
Kampala, UG

Silvia Neciosup

Department of Medical Oncology, National
Institute of Neoplastic Diseases, Lima, PE

Shinji Ohno

Breast Oncology Centre, Cancer Institute
Hospital, Tokyo, JP

Shani Paluch-Shimon

Hadassah University Hospital - Sharett Institute
of Oncology Jerusalem, IL

Ann H. Partridge

Dana-Farber Cancer Institute, Breast Oncology
Dpt. and Adult Survivorship Programme,
Boston, US

Frédérique Penault-Llorca

Jean Perrin Centre, Comprehensive Cancer
Centre, Clermont-Ferrand, FR

Hope S. Rugo

Breast Oncology and Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer
Center, San Francisco, US

Elzbieta Senkus

Medical University of Gdansk, Gdansk, PL

Lillie Shockney

Johns Hopkins University School of Medicine,
Baltimore, US

Andrea Smith

Breast Cancer Network Australia, Camberwell, AU

Richard Sullivan

King's College London, London, UK

Nicholas Turner

Institute of Cancer Research, London, UK

Galina Velikova

University of Leeds, Leeds, UK

Peter Vuylsteke

University of Botswana, Gaborone, BW

Theresa Wiseman

The Royal Marsden NHS Foundation Trust,
University of Southampton, UK

Rachel Würstlein

Breast Center and CCC Munich, LMU University
Munich, DE

Marzia Zambon

Europa Donna - The European Breast Cancer
Coalition, Milan, IT

Breast cancer patient advocacy programme

Representatives of breast cancer patient advocacy groups are warmly invited to participate in ABC7 and actively contribute to the scientific programme and consensus session.

Furthermore, in collaboration with several leading global breast cancer patient advocacy groups, additional patient advocacy sessions dedicated to ABC patients and their carers will be scheduled.

Breast Cancer Patient Advocacy Committee

Coordinator: Fatima Cardoso

ABC Global Alliance, Lisbon, PT

Bertha Aguilar Lopez

MILC Foundation, Mexico City, MX

Elizabeth Bergsten-Nordström

Europa Donna - The European Breast Cancer Coalition, SE

Maria João Cardoso

MamaHelp Association, Lisbon, PT

Runcie C.W. Chidebe

Project PINKBLUE, Abuja, NG

Renate Haidinger

Brustkrebs Deutschland e.V., Munich, DE

Ranjit Kaur

Breast Cancer Welfare Association, Pataling Jaya, MY

Ginny Mason

Inflammatory Breast Cancer Research Foundation, West Lafayette, US

Shirley A. Mertz

MBC US Alliance and Metastatic Breast Cancer Network US, Inverness, US

Claire Myerson

Breast Cancer Now, London, UK

Gertrude Nakigudde

Uganda Women's Cancer Support Organisation, Kampala, UG

Kim Sabelko

Susan G. Komen, Washington, US

Eva Schumacher-Wulf

Mamma Mia, Kronberg, DE

Andrea Smith

Breast Cancer Network Australia, Camberwell, AU



High Patronage

The ABC Global Alliance is proud to announce that the Conference is held under the High Patronage of His Excellency the President of the Portuguese Republic, Prof. Marcelo Rebelo de Sousa.

COM O ALTO PATROCÍNIO
DE SUA EXCELÊNCIA

UNDER THE HIGH PATRONAGE OF THE
PRESIDENT OF THE PORTUGUESE REPUBLIC



O Presidente da República


The ABC Global Alliance is proud to announce that the Conference is held under the Patronage of the European Parliament.



Under the patronage of the European Parliament

European Elections 6-9 June 2024

Floor plan



ABC7 conference and consensus guidelines

The ABC7 guidelines will be published in a peer-review journal, after the Conference.
 The ABC7 guidelines are endorsed by **AGO, ECO, EONS, ESO, EUSOMA, St. Paul Course** and **SIS**.
 The ABC7 Conference is held with the support from **BCRF** and **Susan G. Komen**, under the auspices of **UICC, and** with official representatives of **ABC NZ, ASCO, GECOPERU, NCCN**.
 The ABC7 Conference is endorsed by **AGO, ECO, EONS, ESO, ESSO, ESTRO, EUSOMA, Global Breast Cancer Conference, OECI** and **SIS**.
 Further leading organisations in the field will cooperate and endorse the Conference and guidelines.
 The guidelines from previous editions are published at www.abc-lisbon.org.

Programme outline

All times in the programme are indicated in Western European Time (WET), time zone of Lisbon.
 Please use a time converter to check your time if attending online.

Wednesday, 8 November	Thursday, 9 November		Friday, 10 November	Saturday, 11 November	Sunday, 12 November
	9:00-19:30 Exhibition		8:30-19:30 Exhibition	8:30-13:00 Exhibition	8:30-12:30 ABC Global Alliance meeting: Global Charter Event
	9:00-10:30 Breast cancer patient advocacy session: Beyond my cancer treatments: What else?	9:00-10:30 Projection of Advanced Breast Cancer videos	8:30-10:45 Session	8:30-10:30 Consensus session (part 1)	
	10:30-11:00 Coffee break		10:45-11:15 Coffee break	10:30-11:00 Coffee break	
	11:00-12:30 Breast cancer patient advocacy session: Complexities of shared decision making	11:00-12:30 Projection of Advanced Breast Cancer videos	11:15-13:00 Session	11:00-11:15 Report from ABC Patient Advocacy Committee	
	12:30-13:30 Lunch		13:00-14:00 Lunch and poster session	11:15-12:45 Consensus session (part 2)	
	13:30-15:10 Opening session		14:00-15:30 Session	12:45-13:00 Close	
15:00 - 19:00 REGISTRATION OPENS	15:10-15:50 Session		15:30-15:50 Coffee break	13:30 Lunch	
	15:50-16:20 Coffee break		15:50-18:00 Session	14:30 - 16:00 ABC Global Alliance Meeting: Communication Workshop	
	16:20-18.00 Session			16:00-16h30 Coffee break	
	18:00-19:30 Breast cancer patient advocacy session: The central role of nursing for ABC patients		18:00-19:30 Sponsored satellite symposium	18:00-19:30 Breast cancer patient advocacy session: Rehabilitation to manage disabilities in metastatic breast cancer	
	18:00-19:30 Sponsored satellite symposium		18:00-19:30 Breast cancer patient advocacy session: Rehabilitation to manage disabilities in metastatic breast cancer		
	Welcome cocktail				

Programme

THURSDAY, 9 NOVEMBER 2023

9:00-10:30

Audit. I

Patient advocacy session: Beyond my cancer treatments: What else?

- Over the counter in advanced breast cancer. Fears and questions?
- Integrative Medicine in Advanced Breast Cancer Treatment. The Actual Panorama and how it can be improved.
- The medical oncologist needs. How to deal with no information
- What else besides the cancer medication. What is good and what is bad. The interactions
- Discussion

Chairs: Maria João Cardoso, PT and Renate Haidinger, DE

Maria João Cardoso, PT and Renate Haidinger, DE

Rachel Würstlein, DE

Silvia Neciosup, PE

André Dourado, PT

All

9:00-10:30

Audit. II

Projection of Advanced Breast Cancer videos

10:30-11:00

Coffee break

11:00-12:30

Audit. I

Patient advocacy session: Complexities of shared decision making

- Introduction
- How mental health issues influence shared decision-making
- How to discuss survival times and be prepared for end-of-life care decisions
- Overcoming my fears and being prepared
- Discussion

Chairs: Elizabeth Bergsten Nordström, SE, Ginny Mason, US and Eva Schumacher-Wulf, DE

Elizabeth Bergsten Nordström, SE and Ginny Mason, US

Lesley Fallowfield, UK

Belinda Kiely, AU

Claire Myerson, UK

All

11:00-12:30

Audit. I

Sponsored Lecture

11:00-12:30

Audit. II

Projection of Advanced Breast Cancer videos

12:30-13:30

Lunch

13:30-15:10

Audit. I

Opening session

- Opening - Welcome to Lisbon
- Welcome message from Stella Kyriakides, European Commissioner for Health and Food Safety, on Europe's Beating Cancer Plan and breast cancer
- Welcome to ABC7

Chairs: Fátima Cardoso, PT and Larry Norton, US

Carlos Moedas, Mayor of Lisbon, PT

Stella Kyriakides, BE

Fátima Cardoso, PT

- From daughter to decision maker: The shifting role of a caregiver in metastatic breast cancer Sarah-Jane Barker, UK
- ABC7 Award lecture: The spark that lit the fire - My journeys with ABC patients and their families Lillie Shockney, US

15:10-15:50
Audit. I

Best Abstract Presentation

Chairs: Eric P. Winer, US
and Eva Schumacher-Wulf, DE

- Updated overall survival (OS) outcomes from the phase 3 PHOEBE trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer Xichun Hu, CN
- Enhancing patient care: interim data analysis and patient experience of personalized electronic symptom monitoring led by a specialist nurse for engagement in treatment and improved quality of life in advanced breast cancer Marion Kuper-Hommel, NZ
- The impact on productivity costs of reducing unemployment in patients with advanced breast cancer: A model estimation based on a Portuguese nationwide observational study Leonor Matos, PT
- Discussion All

15:50-16:20

Coffee break

16:20-18:00
Audit. I

Clinical Dilemmas

Chairs: Claire Myerson, UK and
Sandra M. Swain, US

- Impact of new early breast cancer standards in the choice of first line therapies Mariana Chavez MacGregor, US
- How to optimize care for long term responders: to be or not to be on "treatment holidays" Joseph Gligorov, FR
- From DNR to ICU - expanding the rights of ABC patients Ann H. Partridge, US
- New QoL tools for ABC: EU H2O project and EORTC / ABC Global Alliance tool Galina Velikova, UK
- Discussion All

18:00-19:30
Audit. II

Patient advocacy session: The central role of nursing for ABC patients

Chairs: Andrea Smith, AU and
Theresa Wiseman, UK

- Welcome
- What difference can nurses make to the care of patients with ABC? The perspective of patients and family members Andrea Smith, AU
- The specialised metastatic breast care nurse role in Australia. The nurses' role in helping people manage side effects, treatment and emergencies Jenny Gilchrist, AU

- Nursing support for ABC patients: perspective from low and middle-income countries
- Enabling nurses to provide appropriate care for patients with ABC: the development of a specialised training program for ABC nurses
- Discussion

Nanre Mampak, NG

Amanda Drury, IE

Amanda Drury, IE- Vicky Durston, AU - Jenny Gilchrist, AU - Nanre Mampak, NG - Andrea Smith, AU and Theresa Wiseman, UK

18:00-19:30 **Sponsored Lecture**

Audit. I

19:30 *Welcome cocktail*

FRIDAY, 10 NOVEMBER 2023

08:30-09:30 **Biology 1.0**

Audit. I

- Interpreting a NGS report
- Interpreting a liquid biopsy report
- Interpreting a genetic test report
- Discussion

Chairs: Mariana Chavez MacGregor, US and Alexandru Eniu, CH

Nadia Harbeck, DE

Nicholas Turner, UK

Shani Paluch-Shimon, IL

All

9:30-10:45 **Biology 2.0**

Audit. I

- Optimizing molecular subtypes classification
- How low should we go? HER2 low, ER low
- Redefining endocrine resistance
- How can Artificial Intelligence help?
- Discussion

Chairs: Belinda Kiely, AU and Sung-Bae Kim, KR

William J. Gradishar, US

Frédérique Penault-Llorca, FR

Lisa A. Carey, US

Dimitris Kalogeropoulos, UK

All

10:45-11:15 *Coffee break*

11:15-12:15 **Loco-regional highlights**

Audit. I

- When should the primary tumor be treated in ABC?
- Leveraging concomitant radio-targeted therapy for MBC and inoperable LABC
- Revisiting oligometastatic disease
- Discussion

Chairs: Marion Kuper-Hommel, NZ and Elzbieta Senkus, PL

Maria João Cardoso, PT

Brigitte V. Offersen, DK

Prudence A. Francis, AU

All

12:15-13:00 **Improving Imaging of ABC**

Audit. I

- Optimal use of Pet-CT in ABC: new EANM-SNMMI guidelines
- New Imaging technologies for ABC
- Discussion

Chairs: Jyoti Bajpai, IN and William J. Gradishar, US

Lioe-Fee de Geus, NL

Frédéric E- Lecouvet, BE

All

13:00-14:00 **Poster session**

13:00-14:00 *Lunch*

14:00-15:30
Audit. I

Tough issues in ABC. Report from WebSeries

- ABC in a pregnant patient
- Optimal management of inflammatory inoperable LABC and/or MBC
- Optimal management of a patient with ABC in visceral crisis
- Management a patient with ABC and HIV
- Optimal management of an older frail patient with ABC
- Management of leptomenigeal disease

Chairs: Matti S. Aapro, CH and Gertrude Nakigudde, UG
Matteo Lambertini, IT
Karen Gelmon, CA
Hope S. Rugo, US
Peter Vuylsteke, BW
Laura Biganzoli, IT
Volkmar Mueller, DE

15:30-15:50 *Coffee break*

15:50-17:05
Audit. I

The perfect storm: war, recession, regulatory/payers hurdles

- Caring for cancer patients amidst war
- Barriers and inequalities due to old fashion regulatory and / or recruitment rules
- Will the WHO Global Breast Cancer Initiative (GBCI) help ABC patients?
- The new Lancet Commission on BC: a powerful lobbying for ABC
- Discussion

Chairs: Nagi S. El Saghir, LB, Carlos H. Barrios, BR and Marzia Zambon, IT
Richard Sullivan, UK
Bishal Gyawali, CA
André Ilbawi, CH
Charlotte Coles, UK

17:05-18:00
Audit. I

News from ABC6

- HER2+
- ER+ / Her2 Neg
- Triple negative
- Discussion

All
Chairs: Silvia Neciosup, PE and Shinji Ohno, JP
Javier Cortés, ES
Sandra Franco, CO
Rebecca A. Dent, SG

18:00-19:30
Audit. II

Patient advocacy session: Rehabilitation to manage disabilities in metastatic breast cancer

- Introduction
- My multiple burdens of living with MBC, disabilities, poor access to care and workplace issues.
- Relationship between diet and exercise in MBC patients
- Managing Lymphoedema in MBC patients
- Discussion

Chairs: Runcie Chidebe, NG and Ranjit Kaur, MY
Runcie C.W. Chidebe, NG and Ranjit Kaur, MY
Shirley A. Mertz, US
Leonor Matos, PT
Isabelle Aloï-Timeus, MX
All

18:00-19:30
Audit. I

Sponsored Lecture

SATURDAY, 11 NOVEMBER 2023

8:30-10:30 Audit. I	Consensus session (part I)	ABC7 Chairs, Scientific Committee Members and Panellists
10:30-11:00	<i>Coffee break</i>	
11:00-11:15 Audit. I	Report from ABC Patient Advocacy Committee	Runcie C. W. Chibede, NG
11:15-12:45 Audit. I	Consensus session (part II)	ABC7 Chairs, Scientific Committee Members and Panellists
12:45-13:00 Audit. I	<i>Close</i>	



The ABC Global Alliance, established in 2016 as an initiative of the European School of Oncology and now registered as a non-profit association in Portugal, is a multi-stakeholder platform for all those interested in collaborating on common projects related to advanced breast cancer (ABC) around the world. We are made up of people and organisations who are committed to develop, promote and support tangible improvements that will ultimately create awareness and actions that will improve and extend the lives of patients living with ABC worldwide.

The ABC Global Alliance was launched during the World Cancer Congress in Paris on 3 November 2016. It is a continuation of the work developed through the ABC International Consensus Conference created in 2011, responsible for the ESO-ESMO international consensus guidelines for the management of advanced breast cancer and its advocacy efforts.

The ABC Global Alliance invites all interested ABC7 participants to join its meeting that will take place immediately after ABC7 on **11 and 12 November 2023**.

Saturday, 11 November

ABC7 will be followed by the ABC Global Alliance meeting and General Assembly.

Communication Workshop

On Saturday, 11 November from 14:30 to 16:00 Lisbon time, we will be hosting a communication workshop. The workshop will be dedicated to discussing important communication issues related to prognosis and discussing end of life. Five main questions will be asked to all participants:

1. When should the end-of-life discussions happen?
2. Who else, besides the patient, should be present?
3. What should be discussed?
4. Who within the multidisciplinary team should be responsible for the discussion?
5. How might it be best done?

In order to allow participant to express their opinions, the audience will be divided into smaller groups and each group will discuss the same questions. Answers will be collected, discussed, taking into account geographical and cultural differences, and conclusions and future actions will be agreed upon (e.g. potential position paper).

ABC Global Alliance General Assembly (members only)

Internal meeting of ABC Global Alliance will be hosted on Saturday, 11 November from 16:30 to 17:30 Lisbon time. Only members of the Alliance will be granted access.

Sunday, 12 November

In 2025, to mark a decade since the launch of ABC Global Charter, the ABC Global Alliance plans to relaunch the charter with updated goals, to continue to drive change in ABC. To introduce the plan for the relaunch of the ABC Global Charter and discuss initial ideas for its update, the ABC Global Alliance will be holding a half-day working session on Sunday 12 November, from 8:30 until 12:30. The session will be open to all in-person attendees of the ABC7 conference in Lisbon.

Consensus panellists

Matti S. Aapro, CH

Jyoti Bajpai, IN

Carlos H. Barrios, BR

Laura Biganzoli, IT

Fátima Cardoso, PT

Maria João Cardoso, PT

Lisa A. Carey, US

Mariana Chavez MacGregor, US

Runcie C.W. Chidebe, NG

Javier Cortés, ES

Rebecca A. Dent, SG

Nagi S. El Saghir, LB

Alexandru Eniu, CH

Lesley Fallowfield, UK

Prudence A. Francis, AU

Sandra Ximena Franco Millan, CO

Karen Gelmon, CA

Jenny Gilchrist, AU

Joseph Gligorov, FR

William J. Gradishar, US

Nadia Harbeck, DE

Xichun Hu, CN

Ranjit Kaur, MY

Belinda Kiely, AU

Sung-Bae Kim, KR

Marion Kuper-Hommel, NZ

Frédéric E. Lecouvet, BE

Ginny Mason, US

Claire Myerson, UK

Volkmar Mueller, DE

Silvia Neciosup, PE

Larry Norton, US

Birgitte V. Offersen, DK

Shinji Ohno, JP

Shani Paluch-Shimon, IL

Ann H. Partridge, US

Frédérique Penault-Llorca, FR

Hope S. Rugo, US

Eva Schumacher-Wulf, DE

Elzbieta Senkus, PL

Sandra M. Swain, US

Peter Vuylsteke, BW

Eric P. Winer, US

Theresa Wiseman, UK

ABC Award

The ABC Award is aimed at recognising a researcher, physician, nurse or patient advocate who has made an outstanding and impacting contribution in the field of advanced breast cancer throughout his/her career.



The **2023 ABC Award** – in recognition of her tireless work to improve the care of breast cancer patients, and metastatic breast cancer patients in particular, around the world, with an expertise in navigation, survivorship, patient-centred care, quality of life, end-of-life planning and care (with emphasis on the powerful MBC Retreats), improving the cancer patient's experience and clinical outcomes, but also as public speaker and author of many books – will be assigned to **Lillie Shockney** during the award session on Thursday, 9 November.



The **2021 ABC Award** - in recognition of her outstanding advocacy work for all ABC patients worldwide, accomplished through the Metastatic Breast Cancer Network, the Metastatic Breast Cancer Alliance and more recently the Advanced Breast Cancer Global Alliance - was assigned to **Shirley A. Mertz**.



The **2019 ABC Award** - in recognition of her foresight in understanding the importance of advanced breast cancer and for launching a Global Alliance against it - was assigned to **Fatima Cardoso**.



The **2017 ABC Award** - in recognition for her work and dedication to advocacy specifically to advanced breast cancer patients - was assigned to **Musa Mayer**.



The **2015 ABC Award** - in recognition for his work on metastatic breast cancer, especially improving the management of metastatic cancer to bone, resulting in preservation and improvement in quality of life of patients worldwide - was assigned to **Robert E. Coleman**.



The **2013 ABC Award** - in recognition of his work on discovering fundamental, clinically-relevant biological and molecular mechanisms for metastases including site specificity, latency, self-seeding and the role of the microenvironment in colonization and drug resistance - was assigned to **Joan Massagué**.

Poster session

BP: Best poster presentation; **PO:** Poster presentation

BP47 Short films "Matices": highlighting the rights of women with metastatic breast cancer. Alejandra de Cima, MX

BP48 What is a life with MBC worth? The Cancer Currency Campaign: Demanding equitable treatment for those living with metastatic breast cancer. Marzia Zambon, IT

BP49 The financial toxicity of metastatic breast cancer for single mothers: An analysis of where disparities lie and outcomes for quality of life. Roberta Lombardi, US

BP50 Therapy support with a standardized nursing consultation for patients under oral tumor therapy in gynecological oncology (breast cancer and ovarian cancer). Sophie Winkler, DE

BP51 ABC4Nurses: A co-design project to develop, deliver and evaluate an online education programme for nursing caring for people with Advanced Breast Cancer. Theresa Wiseman, UK

BP52 Development of an information film for friends and family of patients with MBC "They just don't know what to say or do". Valerie Jenkins, UK

PO53 Supportive care for metastatic breast cancer. Saptaparna Jana, IN

PO54 Home Based Care for Terminal Cancer Patients: Study from rural part of India. Mandal Nabanita, IN

PO55 Identifying the education, information and support needs of Canadians diagnosed with breast cancer: A Canadian Breast Cancer Network (CBCN) Assessment Project. Cathy Ammendolea, CA

PO56 Psychological distress and its determinants among Moroccan women recently diagnosed with locally advanced breast cancer: A cross-sectional study. Majid Omari, MA

PO57 ABC4Nurses - Advanced Breast Cancer education curriculum for cancer nurses: A Delphi Consensus Study. Amanda Drury, IE

PO58 A systematic review of curricula for advanced breast cancer education for nurses. Amanda Drury, IE

PO59 Uncovered: A breast recognition project for black, indigenous and people of colour with breast cancer. Jasmine Sikand, CA

PO60 The power of a Metastatic Breast Cancer Advocacy Program with engaged allies. MJ DeCoteau, CA

PO61 Highlighting advanced breast cancer in Ghanaian men and women through art. Abena Addai, GH

PO62 Making Metastatic Breast Cancer count. Andrea Smith, AU

PO63 The importance of health literacy for advanced breast cancer patients: ideas and examples from Greece. Effrosyni Tzintziropoulou, GR

PO64 Developing programs to increase access to healthcare and improve quality of life for women with advanced breast cancer. Maricarmen Planas-Silva, US

PO65 Psychological and religious coping strategies in Moroccan women recently diagnosed with locally advanced breast cancer: baseline findings from cohort study. Majid Omari, MA

PO66 Assessing select emotional and psychological states of Stage IV breast cancer patients: A Canadian Breast Cancer Network (CBCN) Assessment Project. Cathy Ammendolea, CA

PO67 "Guiding towards Better Care: Breast Cancer Navigators' Program implementation for increasing patients' satisfaction at a comprehensive cancer center". Mona Elhosary, EG

PO68 "I am still alive": Peer support group for older women with Metastatic Breast Cancer in Nigeria. Runcie C.W. Chidebe, NG

- P069** Capturing life in color: documenting the lived experiences of advanced breast cancer patients. Virginia Leach, US
- P070** Patient Advocacy in Advanced Breast Cancer by Ethel Olomu (Founder Engraced Life Foundation) Engraced Life Foundation is a nonprofit foundation birthed out of empathy and near-death experience in surviving stage 4 metastatic breast cancer in 2010. Ethel Olomu, NG
- P071** Patients want to enhance their self-management possibilities through a side effects management app, as long as ...An inventory. Christine Bettine Boers-Doets, NL
- P072** Is palliative care services at home better than hospice care for advanced breast cancer patients. Gloria Gakii, KE
- P073** Are Community Health Volunteers of any benefit in cancer care? Supportive care is key for patient with life threatening/life limiting illness. Gloria Gakii, KE
- P074** Understanding the needs and opportunities for information in patients with metastatic breast cancer in Tanzania- a qualitative study. Nazima Dharsee, TZ
- P075** A global survey of young adults living with all stages of breast cancer with particular interest in those with metastatic breast cancer, their co-survivors, and the healthcare providers that care for this community. Jennifer Merschdorf, US
- P077** Adapting the middle-range theory of self-care- meeting the day to day needs of women with MBC. Rama Sivaram, IN
- P078** Disease awareness campaign on breast cancer with an ethnic approach among Afro-Colombian population. Juliana Jaramillo, CO
- P080** Nurturing emotional strength: The Holistic Oncology Program for Emotional Well-being (HOPE) for empowering breast cancer patients at Sultan Daeng Radja Hospital. Rifaldy Fajar, ID
- P081** Nurses as patient advocates in resource-restricted countries -experience of Georgia. Nino Laperashvili, GE
- P082** Perspectives of female high school students in Ghana, Namibia, Malawi and Zambia: How lack of access to holistic cancer care fuels advanced breast cancer in Africa. Abena Addai, GH
- P083** Inclusion by design: recommendations for building equity in clinical trials through the lens of metastatic breast cancer. Helena Wilcox, UK
- P084** Lessons learned in developing a treatment access program for advanced breast cancer in low- and middle-income countries. Geoff Cook, US
- P085** Meeting the needs of women with advanced breast cancer in the support setting. Leonie Young, AU
- P088** Increased expression of METTL3 gene in a cohort of Egyptian female patients with locally advanced breast cancer. Raghda Saad Zaghloul Taleb, EG
- P089** Immunohistochemistry and digital image analysis of breast cancer associated fibroblasts' plasticity and their interactions with stromal components and clinico-pathologic parameters. Mihaela-Maria Pasca-Fenesan, RO
- P090** Clinical significance of systemic immune-related markers in estrogen receptor-positive, HER2-negative advanced breast cancer patients receiving eribulin: A multicenter, retrospective study. Junichiro Watanabe, JP
- P091** A liquid biomarker reflecting proliferation rate - thymidine kinase activity - provides unique guidance for predicting therapy efficacy and monitoring of advanced breast cancer. Hanna Ritzén, SE
- P092** The receptor trial: the time has come. Allen Pannell, US
- P093** The prognosis of CTC and its HER2 statute evaluation by a highly sensitive, fully automated, and integrated microfluidic platform. Chao Han, CN
- P097** Impact of tumor immune microenvironment on breast cancer progression. Alisher Kahharov, UZ

BP99 Five years after I'm still here: reporting on changes in advanced breast cancer survival and treatment in New Zealand. Adele Gautier, NZ

PO100 HER2 low metastatic breast cancer pathological and clinical characteristics: a single Mexican institution experience. Maria Tereza Nieto-Coronel, BO

PO101 Role of ultrasound guided biopsy in clinically diagnosed metastatic lesions in patients with breast cancer. An initial experience from resource limited country. Palwasha Gul, PK

PO102 "I prepare my pill jar before I go to work. It is not a problem but a way of living." Experiences of metronomic chemotherapy in patients with metastatic breast cancer – a qualitative interview study. Karolina Larsson, SE

PO103 Brain imaging surveillance in asymptomatic patients with metastatic breast cancer: Patient and physician perspectives. Elena Laakmann, DE

PO104 Comparing efficacy and toxicity in HR+/HER2- metastatic breast cancer patients treated with ribociclib or palbociclib in combination with endocrine therapy: Results from a single center in Mexico. Andrea Maliachi Díaz, MX

PO105 Treatment sequencing and overall survival of HER2-positive advanced breast cancer in a Peruvian institution. Guillermo Valencia, PE

PO106 Survival and prognostic factors in metastatic breast cancer in a cancer center in Nigeria. Mariam Bashir, NG

PO107 Treatment patterns and clinical outcomes among patients receiving CDK4/6 Inhibitors for HR+/HER2- advanced/metastatic breast cancer in a single-centre, Canadian real-world setting using ai-extracted data. Guillaume Feugère, CA

PO108 Lapatinib usage in Tajikistan for women with metastatic breast cancer. Khilola Kakharova, TJ

PO109 Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: A multicenter, retrospective study. Biyun Wang, CN

PO110 Assessment of early progression risk for patient with ESR1 mutations and hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC). Tetiana Tarasenko, UA

PO111 Real world data on the application of endocrine therapy in stage IV hormonal receptor positive breast cancer patients. Mariela Vasileva-Slaveva, BG

PO112 Retrospective analysis of locally advanced breast cancer in Albania: A call for improved treatment strategies. Elvira Kozma, AL

PO113 More is better? Does extended taxane use in combination with trastuzumab improve outcomes in HER2-positive metastatic breast cancer? Alexandra Garcilazo Reyes, MX

PO114 Prevalence and clinical features of HER2-low breast cancer among Ukrainian population. Maryna Bondar, UA

PO115 Real world effectiveness of everolimus-based therapy in hormone-receptor-positive metastatic breast cancer after progression on CDK4/6 inhibitor. Joana Savva-Bordalo, PT

PO116 Cutaneous breast cancer metastases treated with palbociclib. Nektarios Alevizopoulos, GR

PO117 Access to CDK4/6 inhibitors in metastatic luminal breast cancer in Tunisia: A real life story full of challenges. Seif Haddaoui, TN

PO118 Results of anti-HER 2 therapies after brain metastases on the prognosis in breast cancer patients. Karolina Widera, PL

PO119 Survival of young patients with advanced breast cancer stages III and IV. Hiba Moukadem, LB

PO120 Can a breast cancer register measure adherence to national advanced breast cancer (ABC) treatment guidelines in clinical practice? Adele Gautier, NZ

PO121 A comparison of clinicopathological features and prognosis between triple-negative and non-triple negative breast cancer at Ocean Road Cancer Institute. Rugengamanzi Eulade, TZ

- BP132** Local HERO: A Phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to 5 brain metastases from HER2+ breast cancer. (TROG study 16.02). Claire Phillips, AU
- PO133** Radiation induced hypothyroidism in locally advanced breast cancer. Suryakanta Acharya, IN
- PO134** Deep-inspiration breath-hold radiotherapy technique for locally advanced breast cancer: impact on organs at risk. Nigar Aliyeva, AZ
- PO136** Impact of isolated solitary breast cancer liver metastasis surgical resection on common patient health status and ability to proceed chemotherapy. Denys Fedorov, UA
- BP140** Unmasking the impact of inpatient palliative care consultation on patient outcomes in advanced breast cancer patients: A retrospective review. Rana Yamout, LB
- PO141** Cancer and palliative care in rural settings in India. Aditya Manna, IN
- PO142** Psychosocial effects, symptoms and coping strategies in patients with breast cancer receiving neoadjuvant chemotherapy: a qualitative study. Majid Omari, MA
- PO143** Modeling an announcement pathway for patients entering metastatic disease. Marie-Ange Mouret-Reynier, FR
- PO144** Oral hygiene parameters for febrile neutropenia during breast cancer chemotherapy. Mutsumi Fujimoto, JP
- PO145** Development of a health record linkage method for estimating metastatic breast cancer prevalence in New South Wales (NSW), Australia. Andrea Smith, AU
- PO146** How happy are women with advanced breast cancer in a low- and middle-income setting. Yek-Ching Kong, MY
- PO147** The prediction of the prognosis of outpatients with metastatic breast cancer using the double surprise question. Masako Sato, JP
- PO148** A randomized, controlled, parallel-group, trial on the long-term effects of melatonin on fatigue associated with breast cancer and its adjuvant treatments. Seyed Alireza Javadinia, IR
- PO149** Report of the psychological support centre for cancer patients in Nigeria: improving the mental health of metastatic breast cancer patients and others. Runcie C.W. Chidebe, NG
- PO150** The power of positivity: Does optimism moderate the relationship between circadian rhythm disruption and cancer-related fatigue among advanced breast cancer patients? Maria-Chidi C Onyedibe, NG
- PO152** Radiologic monitoring of paraneoplastic cerebellar degeneration from breast cancer. Shinsuke Sasada, JP
- PO154** Development and introduction of methods for risk assessment and diagnosis of hereditary breast cancer in Armenia. Artur Avetisyan, AM
- PO155** Different digital platforms as support tools in the treatment of metastatic breast cancer. Valeria Colomo, PE
- PO156** Prevalence of locally advanced breast cancer and metastatic in Bolivian population: A single institution preliminary data. Maria Tereza Nieto-Coronel, BO

Abstract presenters

Acharya Suryakanta, PAY-W Clinic, India

Addai Abena, Breast Care International, Ghana

Alevizopoulos Nektarios, Evangelismos General Hospital, Greece

Aliyeva Nigar, National Center of Oncology, Azerbaijan

Ammendolea Cathy, Canadian Breast Cancer Network, Canada

Avetisyan Artur, National Center of Oncology, Armenia

Bashir Mariam, Lagos University Teaching Hospital, NSIA-LUTH Cancer Center, Nigeria

Biganzoli Laura, Department of Medical Oncology, Hospital of Prato, Italy

Boers-Doets Christine Bettine, CancerMed Side Effects Institute, Netherlands

Bondar Maryna, National Cancer Institute, Ukraine

Cardoso Maria João, Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation and Lisbon University Faculty of Medicine, Lisbon, Portugal

Carey Lisa A., UNC-Lineberger Comprehensive Cancer Center, United States

Chavez-MacGregor Mariana, Health Services Research, Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, United States

Chidebe Runcie C.W., Project PINK BLUE - Health & Psychological Trust Centre, Nigeria

Cima Alejandra de, Fundación CIMA, Mexico

Colomo Valeria, ONCOSALUD AUNA, Peru

Cook Geoff, The Max Foundation, United States

Cortés Javier, International Breast Cancer Center, Quironsalud Group, Barcelona; Medical Scientia Innovation Research, Barcelona; Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain

DeCoteau MJ, Rethink Breast Cancer, Canada

Dharsee Nazima, Ocean Road Cancer Institute, Tanzania

Díaz Andrea Maliachi, Instituto Nacional de Cancerología, Mexico

Drury Amanda, Dublin City University, Ireland

Elhosary Mona, Patient Navigation Unit, Breast Comprehensive Cancer Center, National Cancer Institute, Cairo Univ., Egypt

Eulade Rugengamanzi, Ocean Road Cancer Institute, Tanzania

Fajar Rifaldy, Yogyakarta State University, Indonesia

Fedorov Denys, State Institute «Shalimov's National Institute of Surgery and Transplantation» to National Academy of Medical Sciences of Ukraine, Ukraine

Feugère Guillaume, eugère Guillaume, Pfizer Canada, Canada

Francis Prudence A., Peter MacCallum Cancer Centre, Melbourne, Australia

Fujimoto Mutsumi, Department of Breast Surgery, Hiroshima University Hospital, Japan

Gakii Gloria, Ongata Ngong Palliative Care Community, Kenya

Gautier Adele, Breast Cancer Foundation NZ, New Zealand

Gelmon Karen, BC Cancer Agency, Department of Medical Oncology, Vancouver, Canada

Geus-Oei Lioe-Fee de, Department of Radiology, Leiden University Medical Center, Leiden. Biomedical Photonic Imaging Group, University of Twente, Enschede. Department of radiation Science & Technology, Technical University of Delft, The Netherlands

Gligorov Joseph, Département d'Oncologie Médicale site hôpital Tenon, Institut Universitaire Cancérologie AP-HP Sorbonne Université Paris; Inserm U938 «Biologie et traitement des cancers», CRSA, Institut Universitaire de Cancérologie AP-HP Sorbonne Université Paris, France

Gul Palwasha, Bolan Medical Complex Hospital, Quetta, Pakistan

Gyawali Bishal, Department of Oncology, Queen's University, Kingston, Canada

Haddaoui Seif, Abderrahmen Mami Hospital, Faculty of Medicine of Tunis; University Tunis Manar, Tunisia

Han Chao, Guangzhou Anfang Bio-tech., China

Harbeck Nadia, Breast Center, Dept. OB&GYN, and CCC Munich, LMU University Hospital, Munich, Germany

Hu Xichun, Fudan University Cancer Hospital, Shanghai, China

Jana Saptaparna, MAS Rural Initiative, India

Jaramillo Juliana, Pfizer SAS, Colombia

Javadinia Seyed Alireza, Sabzevar University of Medical Sciences, Iran

Jenkins Valerie, SHORE-C Brighton & Sussex Medical School, University of Sussex, United Kingdom

Kahharov Alisher, Tashkent State Dental Institute / Oncoschool by Djamila Polatova, Uzbekistan

Kakharova Khilola, Khilola Kakharova, Tajikistan

Kalogeropoulos Dimitrios, IEEE Standards Association Healthcare and Life Sciences Practice, New York, United States; Global Health & Digital Innovation Foundation, London; UCL Global Business School for Health, London, United Kingdom

Kong Yek-Ching, Universiti Malaya, Malaysia

Kozma Elvisa, University Hospital Mother Teresa, Albania

Kuper-Hommel Marion, Te Whatu Ora Waikato, New Zealand

Laakmann Elena, University Medical Center Hamburg-Eppendorf, Germany

Lambertini Matteo, IRCCS Ospedale Policlinico San Martino, University of Genoa, Italy

Laperashvili Nino, Todua Clinic / Association Hope, Georgia

Larsson Karolina, Sahlgrenska University Hospital, Sweden

Leach Virginia, United States

Lecouvet Frédéric, Cliniques universitaires Saint-Luc and Institut du Cancer Roi Albert II, UCLouvain, Brussels, Belgium

Lombardi Roberta, Infinite Strength, Inc., United States

Mandal Nabanita, MAS Rural Initiative; Narikeldaha Prayas, India

Manna Aditya, MAS Clinic & Hospital, India

Maria Stancu Andra, Fundeni Clinical Institute, Romania

Matos Leonor, Breast Unit, Champalimaud Clinical Centre / Champalimaud Foundation, Portugal

Menon Manoj, Fred Hutchinson Cancer Center, United States

Merschdorf Jennifer, Young Survival Coalition, United States

Moukadem Hiba, American University of Beirut Medical Center, Lebanon

Mouret-Reynier Marie-Ange, Centre Jean Perrin, France

Nieto-Coronel Maria Teresa, Oncopalia Center, Bolivia

Offersen Birgitte Vrou, Department of Experimental Clinical Oncology, Department of Oncology, Danish Center for Particle Therapy, Aarhus University Hospital, Denmark

Olomu Ethel, Engraced Life Foundation, Nigeria

Omari Majid, Faculty of Sciences Dhar El Mahraz, Sidi Mohamed Ben Abdellah University, Fez, Morocco

Onyedibe Maria-Chidi C., University of Nigeria Nsukka, Nigeria

Pannell Allen, University of Tennessee, United States

Partridge Ann, Dana-Farber Cancer Institute, Breast Oncology Dpt. and Adult Survivorship Programme, Boston, United States

Pasca-Fenesan Mihaela-Maria, Oncohelp Oncology Center, University of Medicine and Pharmacy Victor Babes Timisoara, Romania

Phillips Claire, Peter MacCallum Cancer Centre, Melbourne, Australia

Planas-Silva Maricarmen, Angelmira's Center for Women with Advanced Cancer, United States

Reyes Alexandra Garcilazo, Instituto Nacional de Cancerología, Mexico

Ritzén Hanna, Biovica, Sweden

Sasada Shinsuke, Hiroshima University Hospital, Japan

Sato Masako, KKR Sapporo Medical Center, Japan

Savva-Bordalo Joana, IPO do Porto, Portugal

Shockney Lillie, Johns Hopkins University School of Medicine, United States

Sikand Jasmine, Rethink Breast Cancer, Canada

Sivaram Rama, Sanjeevani Life beyond Cancer-NGO, India

Smith Andrea, Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW, Australia

Taleb Raghda Saad Zaghloul, Faculty of Medicine, Alexandria University, Egypt

Tarasenko Tetiana, National Cancer Institute, Ukraine

Tzintziropoulou Effrosyni, Hellenic association of women with breast cancer "ALMA ZOIS", Greece

Valencia Guillermo, Instituto Nacional de Enfermedades Neoplásicas, Peru

Vasileva-Slaveva Mariela, Bulgarian Breast and other gynecological Cancers Association, Bulgaria

Vuylsteke Peter, University of Botswana, University of Botswana, Gaborone, Botswana

Wang Biyun, Department of Breast and Urologic Medical Oncology, Fudan University Shanghai Cancer Center, China

Watanabe Junichiro, Juntendo University, Japan

Widera Karolina, III Department of Radiotherapy and Chemotherapy, National Institute of Oncology, Gliwice, Poland

Wilcox Helena, The Health Policy Partnership, United Kingdom

Winkler Sophie, LMU University Hospital, Germany

Wiseman Theresa, The Royal Marsden NHS Foundation Trust, United Kingdom

Würstlein Rachel, LMU University Hospital Munich, Breast Center and CCC Munich, LMU Munich, Germany

Yamout Rana, American University of Beirut Medical Center, Lebanon

Young Leonie, Reach to Recovery International, Australia

Zambon Marzia, EUROPA DONNA - The European Breast Cancer Coalition, Italy

Sponsors

ABC Global Alliance wishes to express its appreciation for the following sponsors for having granted their participation and support to ABC7.

Travel grants and complimentary registrations to participants, support to the conference and to the patient advocacy activities



Participating companies



Exhibiting societies



Sponsored satellite symposia

Thursday 9 November 2023 – 18:00-19:30

Stemline. A Menarini Group sponsored satellite symposium



Current and upcoming treatment strategies after CDK4/6 inhibitors for patients with ER+/HER2- advanced breast cancer

18:00-18:10	Welcome and introduction	Ahmad Awada, BE
18:10-18:40	The current and future treatment landscape for ER+/HER2- mBC	Ahmad Awada, BE
18:40-19:00	Emerging biomarkers in breast cancer: Implementing liquid biopsy ESR1 mutation testing	Fredrik Marme, DE
19:00-19:10	Key takeaways	Ahmad Awada, BE
19:10-19:30	Discussion	All

Symposium faculty

Ahmad Awada, Jules Bordet Cancer Institute Brussels, BE
Fredrik Marme, Uniklinik Mannheim, DE

Friday 10 November 2023 – 18:00-19:30

Daiichi Sankyo/AstraZeneca sponsored satellite symposium



Connecting the dots with antibody-drug conjugates (ADCs): Integrating patient experiences and recent data in metastatic breast cancer (mBC)

18:00-18:10	Welcome and introduction	Sofia Braga, PT
18:10-18:25	Linking data with ADCs into clinical practice: How can we integrate recent data into the mBC treatment landscape?	Sofia Braga, PT
18:25-18:40	Interpreting adverse events associated with ADCs: How can we optimise safety in mBC?	Santiago Escrivá-de-Romani, ES
18:40-18:55	Putting patients' quality of life first: What can we do to improve?	Peter Fasching, DE
18:55-19:25	Panel discussion	All faculty
19:25-19:30	Wrap up and close	Sofia Braga, PT

Symposium faculty

Sofia Braga, Hospital Professor Doutor Fernando Fonseca, EPE, Amadora, PT
Santiago Escrivá-de-Romani, Breast Cancer and Melanoma Group, VHIO, Barcelona, ES
Peter Fasching, Erlangen University Hospital, Erlangen, DE
Barbara Pistilli, Gustave Roussy, Villejuif, FR

Disclosure of conflict of interest

Faculty members have been asked to disclose any potential conflict of interest in relation to their participation in the conference. Potential conflict of interests is considered any of the following:

- Any financial interest in or arrangement with a company whose products or services are discussed in the lecture or that might be considered as part of the consensus process.
- Any financial interest in or arrangement with a competing company.
- Any other financial relationship, direct or indirect, or other situations that might raise the question of bias in the work presented or in the participation in the consensus process, including pertinent commercial or other sources of funding for the speaker or panellist or for the associated department or organisation, personal relationships or direct academic competition.

ABC7 Chairs, Co-Chairs, Scientific Committee members, faculty and panel members

Matti S. Apro: Consultant for Accord Pharmaceuticals, Amgen, BMS, Celgene, Clinigen Group, Daiichi Sankyo, Eisai Co.Ltd, Eli Lilly, Genomic Health (Exact Sciences), G1 Therapeutics, Inc., GlaxoSmithKline (GSK), Helsinn Healthcare SA, Hospira (Pfizer), Johnson & Johnson, Merck, Merck Serono (Merck KGaA), Mundipharma International Limited, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Tesaro (GSK), Teva Pharmaceuticals Industries Ltd., Vifor Pharma. Received honoraria for lectures at symposia of Accord Pharmaceuticals, Amgen, Astellas, Bayer HealthCare Pharmaceuticals (Schering), Biocon, Boehringer Ingelheim, Cephalon, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, Eisai Co., Ltd., Dr Reddy's Laboratories, Genomic Health (Exact Sciences), Glenmark Pharmaceuticals Limited, GSK, Helsinn Healthcare SA, Hospira (Pfizer), Ipsen, Janssen Biotech, Kyowa Kirin Group, Merck, Merck Serono (Merck KGaA), Mundipharma International Limited, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Sanofi, Tesaro (GSK), Taiho Pharmaceutical, Teva Pharmaceutical Industries Ltd., Vifor Pharma. Grant/Research supports: Amgen, Eisai, Genomic Health (Exact Sciences), Helsinn, Hospira, Novartis, Merck, Mundipharma, Pfizer, Roche, Sandoz, Tesaro, Teva, Vifor.

Isabelle Aloï-Timeus: Not received

Jyoti Bajpai: Institutional financial interests for conducting research: Eli Lilly, MSD, Novartis, Roche, Paxman Coolers Ltd, Samsung Bioepis co. Ltd, Sun Pharma.

Sarah-Jane Barker: No significant relationships

Carlos H. Barrios: Receipt of grants/research supports: (to the institution) Nektar, Pfizer, Polyphor, Amgen, Daiichi Sankyo, Sanofi, Exelixis, Regeneron, Novartis, GSK, Janssen, OBI Pharma, Lilly, Seagen, Roche, BMS, MSD, Merck Serono, AstraZeneca, Novocure, Aveo Oncology, Takeda, TRIO, PharmaMar, Celgene, PPD, Syneos Health, Labcorp, ICON, IQVIA, Parexel, Nuvisan, PSI, Worldwide, Gilead Sciences, Bayer, Servier. Receipt of honoraria or consultation fees: Advisory Boards and Consulting: Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, AstraZeneca, Zodiac, Lilly, Sanofi, Daiichi. Stock shareholder: Ownership or stocks: Tummi, MEDSir.

Elizabeth Bergsten Nordström: No significant relationships

Laura Biganzoli: Receipt of grants/research supports: Celgene, Genomic Health, Novartis. Receipt of honoraria or consultation fees: AZ, Daiichi-Sankyo, Eisai, Exact Sciences, Gilead, Lilly, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Seagen, Amgen, Boehringer-Ingelheim.

Fátima Cardoso: Receipt of honoraria or consultation fees: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, Gilead, GlaxoSmithKline, Iqvia, MacroGenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seagen, Teva, Touchime.

Maria João Cardoso: Not received

Lisa A. Carey: Other support: Research funding (institution): NanoString Technologies, Seagen, Veracyte, AstraZeneca. Uncompensated relationships: Lilly, Seagen, Novartis, Genentech/Roche, GlaxoSmithKline.

Mariana Chavez Mac Gregor: Receipt of grants/research supports: BCRF, Susan G Komen. Receipt of honoraria or consultation fees: Astra Zeneca, Pfizer, Lilly, Roche, Merck

Runcie C. W. Chidebe: No significant relationships.

Charlotte Coles: Not received

Javier Cortés: Receipt of grants/research supports: Roche, Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, HiberCell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, Reveal Genomics, Expreszion Biotechnologies. Receipt of honoraria or consultation fees: Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme, Daiichi Sankyo, Astrazeneca. Stock shareholder: MedSIR, Nektar Pharmaceuticals, Leuko (relative). Other support: Research funding to the Institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piquar Therapeutics, Puma C, Queen Mary University of London. Travel, accommodation, expenses: Roche, Novartis, Eisai, pfizer, Daiichi Sankyo, Astrazeneca, Gilead. Patents: Pharmaceutical Combinations of a P3k Inhibitor and A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A. ISSUED. Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cortés. US 2019/ 0338368 A1. LICENSED.

Alberto Costa: No significant relationships

Lioe-Fee de Geus-Oei: No significant relationships

Rebecca A. Dent: Receipt of grants/research supports: AstraZeneca, Roche. Receipt of honoraria or consultation fees: AstraZeneca, DKSH, Eisai, Merck, Novartis, Pfizer, Roche.

André Dourado: No significant relationships

Amanda Drury: Receipt of grants/research supports: Pfizer Inc. Receipt of honoraria or consultation fees: European Commission/HADEA; Pfizer Inc.

Vicki Durston: No significant relationships

Nagi S. El Saghir: Receipt of honoraria or consultation fees: Roche, Novartis, Lilly.

Alexandru Eniu: Not received

Lesley Fallowfield: Receipt of grants/research supports: Novartis, Bristol-Myers Squibb, Lilly. Receipt of honoraria or consultation fees: Voluntis, Genomic Health, NanoString Technologies, Novartis, Pfizer, MSD, Novartis, Abbvie, Clovis Oncology, Puma Biotechnology, AstraZeneca, Takeda, Genomic Health/Exact Sciences, Lilly, Seagen, Roche.

Prudence A. Francis: No significant relationships

Sandra Ximena Franco Millan: Receipt of honoraria or consultation fees: Novartis, Pfizer, Eli Lilly. Participation in a sponsored speakers' bureau: Novartis, Pfizer, Eli Lilly.

Karen Gelmon: Receipt of grants/research supports: Pfizer, AstraZeneca. Receipt of honoraria or consultation fees: Pfizer, Lilly, Novartis, AstraZeneca, Merck, Gilead, Seagen.

Jenny Gilchrist: Receipt of honoraria or consultation fees: Eli-Lilly, AstraZeneca, Novartis, Pfizer, MSD, Gilead, Juniper Biologics.

Joseph Gligorov: Receipt of grants/research supports: Eisai, Exact Science, Guardant, Roche Genentech. Receipt of honoraria or consultation fees: Astra Zeneca, Daiichi, Eisai, Evapharma, Exact Science, Gilead, Guardant Lilly, Merck, Novartis, Onxeo, Pfizer, Roche Genentech, Seattle Genetics. Participation in a sponsored speakers' bureau: Eisai, Eva Pharm, Novartis, Roche Genentech, Seattle Genetics. Other support (please specify): Institutional: Institut Universitaire de Cancérologie AP-HP Sorbonne Université; French breast cancer guidelines St Paul.

William J. Gradishar: Not received

Bishal Gyawali: Not received

Renate Haidinger: No significant relationships

Nadia Harbeck: Receipt of grants/research supports: all to institution. Receipt of honoraria or consultation fees: Amgen, AstraZeneca, Daiichi-Sankyo, Gilead, Lilly, MSD, Novartis, Pierre-

Fabre, Pfizer, Roche, Sandoz, Sanofi, Seagen, Viatrix, Zuelligpharma. Participation on a sponsored speakers' bureau: EPG Communication, MEDSCAPE, Springer. Stock shareholder: WSG minority ownership. Spouse/Partner: Consulting for WSG.

Xichun Hu: No significant relationships

André Ilbawi: Not received

Dimitris Kalogeropoulos: Not received

Ranjit Kaur: Receipt of grants/research supports: Novartis, Roche, Pfizer, Astrazeneca. Receipt of honoraria or consultation fees: Novartis, Roche, Pfizer, Astrazeneca. Participation in a sponsored speakers' bureau: Novartis, Roche, Pfizer, Astrazeneca.

Belinda Kiely: Receipt of honoraria or consultation fees: Speakers fees: Novartis, Eisai. Advisory boards: Roche, Gilead, Novartis. Other support (please specify): meeting registrations fees: Novartis, Pfizer, MSD.

Sung-Bae Kim: Receipt of grants/research supports: Novartis, Sanofi-Aventis, and DongKook Pharm Co. Receipt of honoraria or consultation fees: Novartis, AstraZeneca, Lilly, Dae Hwa Pharmaceutical Co. Ltd, ISU Abxis, OBI pharma, Beigene and Daiichi-Sankyo. Stock shareholder: Genopeaks.

Marion Kuper-Hommel: Receipt of honoraria or consulting fees: Astra Zeneca.

Matteo Lambertini: Receipt of grants/research supports: Gilead (to the institution). Receipt of honoraria or consulting fees: Roche, Lilly, Novartis, AstraZeneca, Pfizer, Seagen, Gilead, MSD, Exact Sciences. Participation in a sponsored speakers' bureau: Roche, Lilly, Novartis, Pfizer, Takeda, Ipsen, Sandoz, Libbs, Knight, Daiichi Sankyo. Other support, travel grant: Gilead.

Frédéric E. Lecouvet: Not received

Nanre Mampak: No significant relationships

Ginny Mason: Participation in a sponsored speakers' bureau: Novartis

Leonor Matos: No significant relationships

Shirley A. Mertz: No significant relationships

Volkmar Müller: Receipt of grants/research supports: Institutional research support from Novartis, Roche, Seagen, Genentech, Astra

Zeneca. Receipt of honoraria or consultation fees: Speaker honoraria: Astra Zeneca, Daiichi-Sankyo, Eisai, GSK, Pfizer, MSD, Medac, Novartis, Roche, Seagen, Onkowsen, high5 Oncology, Medscape, Gilead, Pierre Fabre. Consultancy honoraria from Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, Sanofi, Seagen, Gilead, Stemline, ClinSol. Other support (please specify): Travel grants: Roche, Pfizer, Daiichi Sankyo, Gilead.

Claire Myerson: Receipt of honoraria or consultation fees: Novartis Pharma.

Gertrude Nakigudde: No significant relationships

Silvia Neciosup: Receipt of grants/research supports: Roche, Pfizer. Participation in a sponsored speakers' bureau: Tecnofarma, AZ, Roche, Pfizer.

Larry Norton: Receipt of honoraria or consultation fees: Blackrock QLS Advisors, Cold Spring Harbor Laboratory, UNC Breast Spore EAB Meeting, Codagenix Scientific Advisory Board Meeting, Martell Diagnostic Laboratories, Inc., Celgene, Agenus, Immix Biopharma, Inc.

Birgitte V. Offersen: No significant relationships

Shinji Ohno: Participation in a sponsored speakers' bureau: Chugai, Lilly, MSD, Nippon Kayaku.

Shani Paluch-Shimon: Receipt of grants/research supports: Pfizer. Receipt of honoraria or consultation fees: Pfizer, Lily, Novartis, Astra Zeneca, Roche, MSD, Gilead, Rhenium/Exact Sciences, Stemline, Daichi Sankyo. Participation in a sponsored speakers' bureau: Pfizer, Lily, Novartis, Astra Zeneca, Roche, MSD, Gilead.

Ann H. Partridge: Other support (please specify): Uptodate Royalties

Frederique Penault-Llorca: Not received

Hope S. Rugo: Receipt of grants/research supports: Astellas Pharma Inc.; AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche AG/Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Pionyr Immunotherapeutics; Sermonix Pharmaceuticals Inc.; Taiho Oncology, Inc. and Veru Inc. Receipt of honoraria or consultation fees: Puma, NAPO, Blueprint, and Scorpion Therapeutics Daichi Sankyo.

Eva Schumacher-Wulf: No significant relationships

Elzbieta Senkus: Receipt of honoraria or consultation fees: AstraZeneca, Cancérodigest, Curio Science, Egis, Eli Lilly, Exact Sciences, Gilead, high5md, MSD, Novartis, Oncompass Medicine, Pfizer, Pierre Fabre, Roche. Stock shareholder: AstraZeneca, Eli Lilly, Pfizer. Other support: travel support: Amgen, Egis, Gilead, Novartis, Pfizer, Roche. Contracted research: Amgen, AstraZeneca, Eli Lilly, Novartis, OBI Pharma, Pfizer, Roche, Samsung. Medical writing: AstraZeneca, Eli Lilly. Royalties: Springer.

Lillie Shockney: Not received

Andrea Smith: No significant relationships

Richard Sullivan: No significant relationships

Sandra M. Swain: Receipt of grants/research supports: Kailos Genetics, Genentech/Roche. Receipt of honoraria or consultation fees: Athenex, AstraZeneca, Biotheranostics, Natera, Exact Sciences, Lilly, Merck, Genentech/Roche, Sanofi, Daiichi Sankyo, Molecular Templates, Napo Pharmaceuticals. Stock shareholder: SEAGEN. Other support: CO- PI of INAVO 122 Genentech/Roche with in kind travel to investigator meetings, Travel related expenses in kind Sanofi and Daiichi Sankyo.

Nicholas Turner: Receipt of grants/research supports: Astra Zeneca, Pfizer, Roche/Genentech, Merck Sharpe & Dohme, Guardant Health, Invitae, Inivata, Personalis, Natera. Receipt of honoraria or consultation fees: Astra Zeneca, Lilly, Pfizer, Roche/Genentech, Novartis, GlaxoSmithKline, Repare therapeutics, Relay therapeutics, Zentalis, Gilead, Inivata, Guardant, Exact Sciences.

Galina Velikova: Not received

Peter Vuylsteke: Receipt of grants/research supports: UICC grant. Receipt of honoraria or consultation fees: Roche, Novartis and MSD.

Eric P. Winer: No significant relationships

Theresa Wiseman: Receipt of grants/research supports: Receiver of SPCC Pfizer grant.

Rachel Würstlein: Receipt of grants/research supports: Institutional only. Receipt of honoraria or consultation fees: Agendia, Amgen, APOGHEVA, Aristo, Astra Zeneca, Celgene, Clinsol, Clovis Oncology, Daiichi-Sankyo, Eisai, Exact Sciences, Gilead, Glaxo Smith Kline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Mylan, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, PINK, PumaBiotechnolgy, Riemser, Roche, Sandoz/Hexal, Sanofi Genzyme, Seattle Genetics /Seagen, Stemline, Tesaro Bio, Teva, Veracyte, Viatrix. Participation in a sponsored speakers' bureau: Agendia, Amgen, APOGHEVA, Aristo, Astra Zeneca, Celgene, Clinsol, Clovis Oncology, Daiichi-Sankyo, Eisai, Exact Sciences, Gilead, Glaxo Smith Kline, Hexal, Lilly, Medstrom Medical, MSD, Mundipharma, Mylan, Nanostring, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, PINK, PumaBiotechnolgy, Riemser, Roche, Sandoz/Hexal, Sanofi Genzyme, Seattle Genetics /Seagen, Stemline, Tesaro Bio, Teva, Veracyte, Viatrix.

Marzia Zambon: No significant relationships

Uncovered

The truth about working with advanced breast cancer

#actABC

Nurse →

"THE SIDE EFFECTS OF THE TREATMENT OF ABC HAVE CAUSED SO MUCH CHANGE IN MY PHYSICAL, EMOTIONAL AND SOCIAL ECONOMIC HEALTH AND THERE ISN'T ANYTHING I CAN DO ABOUT IT."



ASSISTANT DIRECTOR AT A GOVERNMENT AGENCY →

"EMPLOYERS SHOULDN'T FEEL 'SHE HAS CANCER, SHE IS GOING TO DIE.'"



MALAYSIA ♀

Senior lead advisory →

Diagnosed with ABC in June 2015.

Clare



Not working at the moment →

38-year-old male

"Having a suppressed immune system, I would not feel safe working in an office and commuting given the current state of the pandemic."

United Kingdom ♀

"Since I was diagnosed with BC, I have achieved a Diploma in Economics, a Masters in Business Administration, changed job and have also advanced in my career."



Malta ♀

PROJECT MANAGER →

DIAGNOSED WITH ABC IN MARCH 2018.

"I DIDN'T WANT TO BE KNOWN AS 'THE LADY WITH CANCER'"



UNITED KINGDOM ♀

CHILD EDUCATOR →



MEXICO ♀

DATE DUE
"WORK KEEPS YOU AWAY FROM NEGATIVE THOUGHTS."




Teacher →

Diagnosed with ABC in June 2018.

"The costs associated with my periodic medical reviews are unimaginable and a huge burden on me."



Nigeria ♀



From the
ABC
GlobAlliance

In collaboration with
WORKING WITH CANCER®

Let's make life with ABC work

abcglobalalliance.org

#actABC
Follow us on
Twitter and Facebook
@ABCGlobalAll



Advanced
Breast Cancer
Eighth International
Consensus Conference



Bridging the Gap

6-8 November 2025
Lisbon, Portugal

SAVE THE DATE

Connecting the dots with ADCs: Integrating patient experiences and recent data in metastatic breast cancer

Friday 10 November 2023
18:00–19:30 UTC | Auditorium 1

Throughout the
symposium, we will hear
from patients on their
real-world experiences
with metastatic
breast cancer

How are emerging data changing the metastatic breast cancer landscape and how can we improve patients' quality of life? These key questions will be explored throughout our symposium and in our interactive fireside expert panel discussion.



Welcome and introduction (10 mins)

Professor Sofia Braga (Chair)

Hospital Professor Doutor Fernando Fonseca, EPE, Amadora, Portugal



Linking data with ADCs into clinical practice:

How can we intergrate recent data into the mBC treatment landscape? (15 mins)

Dr Barbara Pistilli

Gustave Roussy, Villejuif, France



Interpreting adverse events associated with ADCs:

How can we optimise safety in mBC? (15 mins)

Dr Santiago Escrivá-de-Romaní

Breast Cancer and Melanoma Group, VHIO, Barcelona, Spain



Putting patients' quality of life first:

What can we do to improve? (15 mins)

Professor Peter Fasching

Erlangen University Hospital, Erlangen, Germany

Panel discussion (30 mins)

All faculty, moderated by Chair

Light refreshments will be
available before the symposium

Wrap-up and close (5 mins)

Moderated by Chair



ABC Global Alliance
c/o Fundação Champalimaud,
Avenida de Brasília s/n
1400-038 Lisboa, Portugal
www.abcglobalalliance.org
@ABCGlobalAll